MedPath

Tagged News

Benralizumab Shows Superior Long-Term Outcomes in Eosinophilic Granulomatosis with Polyangiitis

Monoclonal AntibodyRare Disease
  • The MANDARA study extension demonstrates that benralizumab maintains remission in 62.1% of EGPA patients through 104 weeks, with 43.9% achieving complete oral glucocorticosteroid withdrawal.
  • Benralizumab's superior eosinophil depletion mechanism, targeting IL-5 receptors rather than IL-5 directly, provides more complete and rapid eosinophil suppression compared to mepolizumab.
  • Real-world evidence confirms that IL-5 pathway inhibitors significantly reduce disease burden, with mepolizumab showing 18% reduction in daily oral corticosteroid use and 49% decrease in EGPA-related hospitalizations.
  • The convenience advantage of benralizumab's monthly dosing versus mepolizumab's requirement for three monthly injections may improve patient compliance and treatment outcomes.

Roche's PiaSky Becomes First Subcutaneous PNH Therapy Approved in EU

Drug ApprovalMonoclonal AntibodyRare Disease
  • Roche's PiaSky (crovalimab) has received European Commission approval as the first subcutaneous therapy for paroxysmal nocturnal haemoglobinuria (PNH) that can be self-administered monthly at home.
  • The approval is based on COMMODORE 2 trial data showing PiaSky was equivalent to AstraZeneca's Soliris in controlling red blood cell destruction while reducing blood transfusion needs.
  • PiaSky now has regulatory clearance in the top four global pharmaceutical markets including China, Japan, the US, and EU, positioning it to compete with established intravenous therapies.
  • The drug faces emerging competition from oral therapies including Novartis' recently approved Fabhalta, which analysts predict could reach $3.6 billion in peak annual sales.

A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors

NCT04434092Active, Not RecruitingPhase 3
Hoffmann-La Roche
Posted 10/8/2020

Japanese Intergroup Phase III Trial Evaluates Ramucirumab Plus Irinotecan for Third-Line Advanced Gastric Cancer Treatment

Monoclonal AntibodyOncology
  • A large-scale Japanese intergroup phase III trial is investigating ramucirumab plus irinotecan versus irinotecan alone for patients with advanced gastric cancer who have progressed on prior ramucirumab-containing therapy.
  • The study recruits patients from 110 institutions across 9 clinical trial groups in Japan, with a primary endpoint of overall survival and an assumed hazard ratio of 0.77.
  • As of January 2018, 87 of the planned 400 patients had been enrolled, representing the first major trial to evaluate sustained VEGF blockade in the third-line setting for gastric cancer.
  • Preliminary data from a separate phase II study demonstrated the feasibility of irinotecan-based combinations in second-line gastric cancer, with manageable toxicity profiles and encouraging survival outcomes.

Amgen Challenges Bristol-Myers Squibb Patents for Opdivo-Yervoy Combination Therapy in Patent Review Proceedings

Monoclonal Antibody
  • Amgen filed three inter partes review petitions on February 28, 2025, challenging Bristol-Myers Squibb patents covering combination treatment methods using Opdivo (nivolumab) and Yervoy (ipilimumab).
  • The challenged patents cover methods for treating various cancers including melanoma and microsatellite instability-high colorectal cancer using the anti-PD-1 and anti-CTLA-4 antibody combination.
  • Amgen is currently conducting Phase III trials for ABP 206, an investigational biosimilar of Opdivo, marking the first patent challenge to Opdivo by a potential biosimilar competitor.
  • Bristol-Myers Squibb reported $5.35 billion in U.S. sales for Opdivo in 2024, highlighting the significant commercial stakes involved in this patent dispute.

Fatal Immune Checkpoint Inhibitor Overlap Syndrome: New Case Series Reveals Critical Management Insights

Monoclonal Antibody
  • A Spanish case series documents four patients who developed the rare but deadly myocarditis-myositis-myasthenia gravis (MMM) overlap syndrome following immune checkpoint inhibitor therapy, with mortality rates reaching 40-60%.
  • The syndrome typically manifests within 21 days of treatment initiation, presenting with cardiac arrhythmias, muscle weakness, and respiratory complications requiring immediate aggressive immunosuppression.
  • Early combination therapy with corticosteroids and intravenous immunoglobulin showed improved outcomes, with one case achieving complete recovery using rituximab and tocilizumab for refractory symptoms.
  • The research identifies anti-titin antibodies and complement activation as potential biomarkers, while highlighting the need for routine creatine kinase monitoring during initial treatment cycles.

Immune Profiles Evolution Under Immunotherapy for Melanoma

NCT04576429RecruitingNot Applicable
Assistance Publique - Hôpitaux de Paris
Posted 1/27/2021

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

NCT04438382TerminatedPhase 2
ECOG-ACRIN Cancer Research Group
Posted 1/7/2021

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

NCT04038619RecruitingPhase 1
M.D. Anderson Cancer Center
Posted 2/1/2021

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

NCT03999749Active, Not RecruitingPhase 2
NYU Langone Health
Posted 6/11/2019

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

NCT04691817RecruitingPhase 1
Abramson Cancer Center at Penn Medicine
Posted 7/25/2023

TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma

NCT03293784CompletedPhase 1
Institut Claudius Regaud
Posted 10/16/2017

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

NCT05034536RecruitingPhase 2
Massachusetts General Hospital
Posted 2/7/2022

Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients

NCT04107311Recruiting
University Health Network, Toronto
Posted 9/5/2019

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

NCT04407247RecruitingPhase 1
M.D. Anderson Cancer Center
Posted 7/9/2020

Preventing Toxicity in Renal Cancer Patients Treated With Immunotherapy Using Fecal Microbiota Transplantation

NCT04163289Active, Not RecruitingPhase 1
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Posted 1/23/2020

Vedolizumab for Immune Mediated Colitis

NCT04797325RecruitingPhase 2
University of Copenhagen
Posted 8/30/2021

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

NCT03819296RecruitingPhase 1
M.D. Anderson Cancer Center
Posted 2/21/2021

New Study Highlights Benefits of Maintaining High Factor VIII Levels in Hemophilia A Patients

Monoclonal AntibodyDrug Approval
• Maintaining high Factor VIII (FVIII) levels in people with hemophilia A provides significant clinical benefits, including reduced bleeding risk and better joint health preservation.
• Despite advances in prophylactic treatment, standard-of-care prophylaxis does not completely prevent joint damage or chronic pain, with approximately 47% of hemophilia patients experiencing ongoing pain.
• Recent innovations in hemophilia treatment, including extended half-life therapies, non-factor replacement options, and gene therapy, offer new approaches to sustaining higher FVIII levels and improving patient outcomes.

BAX 855 PK-guided Dosing

NCT02585960CompletedPhase 3
Baxalta now part of Shire
Posted 11/23/2015

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A

NCT03020160CompletedPhase 3
Hoffmann-La Roche
Posted 1/30/2017

A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A

NCT04161495CompletedPhase 3
Bioverativ, a Sanofi company
Posted 11/19/2019

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors

NCT02847637CompletedPhase 3
Hoffmann-La Roche
Posted 9/27/2016

A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors

NCT02795767CompletedPhase 3
Hoffmann-La Roche
Posted 7/22/2016

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors

NCT02622321CompletedPhase 3
Hoffmann-La Roche
Posted 11/18/2015

Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A

NCT00243386CompletedPhase 4
Baxalta now part of Shire
Posted 1/4/2006

Cancer Monoclonal Antibody Partnerships Surge with 599 Deals Recorded Since 2016

Monoclonal AntibodyOncology
  • A comprehensive analysis reveals 599 cancer monoclonal antibody collaboration and licensing deals have been announced since 2016, demonstrating sustained industry investment in this therapeutic area.
  • The deals encompass multicomponent partnerships that typically begin with collaborative research and development and progress to commercialization of therapeutic outcomes.
  • Leading biopharma companies are actively pursuing cancer monoclonal antibody partnerships, with detailed financial terms including upfront payments, milestone payments, and royalty structures being tracked across transactions.
  • The report identifies the top 25 most active companies in cancer monoclonal antibody dealmaking, providing insights into partnership strategies and market dynamics in oncology therapeutics.

Bevacizumab Benefits in Colorectal Cancer Limited to Two-Year Window, New Analysis Reveals

Monoclonal AntibodyOncology
  • A comprehensive review presented at the 2025 ASCO Gastrointestinal Cancers Symposium reveals bevacizumab (Avastin) provides survival benefits in colorectal cancer patients for approximately two years after initial administration.
  • Researchers found that after 20-24 months, the initial survival benefit from bevacizumab diminishes, potentially explaining the crossover of survival curves observed in the PARADIGM trial compared to panitumumab (Vectibix).
  • The study suggests bevacizumab treatment may lead to selection of more aggressive tumor clones over time, characterized by accelerated growth and invasiveness after the initial period of tumor stasis and shrinkage.

5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC)

NCT00433927Unknown StatusPhase 3
PD Dr. med. Volker Heinemann
Posted 1/1/2007

Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer

NCT00096278CompletedPhase 3
National Cancer Institute (NCI)
Posted 9/15/2004

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

NCT00265850CompletedPhase 3
Alliance for Clinical Trials in Oncology
Posted 11/1/2005

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

NCT00819780CompletedPhase 2
Amgen
Posted 4/24/2009

Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer

NCT00112918CompletedPhase 3
Hoffmann-La Roche
Posted 12/1/2004

Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC

NCT02394795CompletedPhase 3
Takeda
Posted 5/29/2015

Immunotherapy Advances Show Promise for Pediatric Osteosarcoma Treatment

CAR-TMonoclonal Antibody
  • Pediatric osteosarcoma remains a challenging malignancy with poor prognosis despite treatment advances, with pulmonary metastasis occurring in over 85% of metastatic cases.
  • The tumor microenvironment plays a crucial role in disease progression, with tumor-associated macrophages and T cells being predominant immune infiltrates that influence patient outcomes.
  • Emerging immunotherapies including mifamurtide, CAR-T cell therapy, and immune checkpoint inhibitors demonstrate therapeutic potential, though overcoming immunosuppressive factors remains essential.
  • Novel prognostic biomarkers within the immune microenvironment, including immune-related gene signatures and inflammatory markers, could guide individualized treatment strategies.

A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors

NCT02107963CompletedPhase 1
National Cancer Institute (NCI)
Posted 2/28/2014

SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas

NCT02301039CompletedPhase 2
Sarcoma Alliance for Research through Collaboration
Posted 3/1/2015

Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma

NCT00902044Active, Not RecruitingPhase 1
Baylor College of Medicine
Posted 2/11/2010

Visugromab Plus Nivolumab Shows Promise in Anti-PD-1 Refractory Solid Tumors by Targeting GDF-15 Pathway

Monoclonal Antibody
  • Visugromab (CTL-002), a GDF-15 neutralizing antibody, combined with nivolumab demonstrated initial efficacy in the phase 2A GDFATHER-TRIAL for patients with advanced solid tumors that had relapsed or were refractory to prior anti-PD-1/PD-L1 therapy.
  • GDF-15 plays a critical role in tumoral immunosuppression by blocking immune cell entry into the tumor microenvironment and interfering with immune synapse formation, which many tumors exploit to resist immunotherapy.
  • The combination therapy represents a novel approach to overcome immunotherapy resistance by neutralizing GDF-15's immunosuppressive effects and potentially restoring T-cell function in the tumor microenvironment.
  • This therapeutic strategy addresses a significant unmet medical need for patients whose cancers have progressed on checkpoint inhibitor therapy, offering a potential pathway to re-sensitize tumors to immune-based treatments.

A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma

NCT05864924CompletedPhase 1
BioSyngen Pte Ltd
Posted 5/10/2023

The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia

NCT06307600RecruitingEarly Phase 1
Anhui Provincial Hospital
Posted 3/15/2024

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

NCT05351788RecruitingPhase 2
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Posted 5/20/2022

Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma

NCT05460767RecruitingPhase 1
Innovent Biologics (Suzhou) Co. Ltd.
Posted 8/31/2022

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

NCT04594642RecruitingPhase 1
AstraZeneca
Posted 3/2/2021

ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors

NCT05276609RecruitingPhase 1
Shanghai Hansoh Biomedical Co., Ltd
Posted 11/28/2021

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

NCT05821933RecruitingPhase 1
RemeGen Co., Ltd.
Posted 9/7/2023

PRediction Of Five Usual Tumors Using Blood Test for Risk Assessment and Early Detection

NCT05874648Not Yet Recruiting
Sixth Affiliated Hospital, Sun Yat-sen University
Posted 7/7/2023

Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases

NCT01792934Active, Not RecruitingNot Applicable
Radboud University Medical Center
Posted 5/1/2013

Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

NCT05745623RecruitingPhase 1
Beijing InnoCare Pharma Tech Co., Ltd.
Posted 12/27/2022

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374RecruitingPhase 3
Merck Sharp & Dohme LLC
Posted 6/24/2024

Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

NCT04650581Active, Not RecruitingPhase 3
Canadian Cancer Trials Group
Posted 1/27/2021

SKB264 Monotherapy in Selected Subjects with Advanced Solid Tumors

NCT05631262Active, Not RecruitingPhase 2
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Posted 11/30/2022

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

NCT03539536Active, Not RecruitingPhase 2
AbbVie
Posted 10/10/2018

An Open-label, Multicenter Study of ZL-1310 in Subjects With Small Cell Lung Cancer

NCT06179069RecruitingPhase 1
Zai Lab (Shanghai) Co., Ltd.
Posted 1/23/2024

A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

NCT04685226RecruitingPhase 1
Beijing InnoCare Pharma Tech Co., Ltd.
Posted 9/27/2020

HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid Tumors

NCT05102214RecruitingPhase 1
Shanghai Henlius Biotech
Posted 5/3/2022

Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

NCT04728633Active, Not RecruitingPhase 2
Thomas Jefferson University
Posted 9/27/2021

Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

NCT02073994CompletedPhase 1
Institut de Recherches Internationales Servier
Posted 3/1/2014

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

NCT03145181Active, Not RecruitingPhase 1
Janssen Research & Development, LLC
Posted 5/16/2017

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer

NCT04505826CompletedPhase 1
Olema Pharmaceuticals, Inc.
Posted 8/13/2020

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

NCT06084884Active, Not RecruitingPhase 1
AstraZeneca
Posted 12/14/2023

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

NCT04607421Active, Not RecruitingPhase 3
Pfizer
Posted 12/21/2020

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

NCT04802590RecruitingPhase 2
The Lymphoma Academic Research Organisation
Posted 1/24/2022

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

NCT04728893RecruitingPhase 2
Merck Sharp & Dohme LLC
Posted 4/5/2021

Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

NCT06536400RecruitingPhase 1
Haisco Pharmaceutical Group Co., Ltd.
Posted 6/25/2024

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

NCT04484623Active, Not RecruitingPhase 3
GlaxoSmithKline
Posted 10/1/2020

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

NCT04696731Active, Not RecruitingPhase 1
Allogene Therapeutics
Posted 2/24/2021

Pilot Study of Anlotinib With STUPP Regimen for Patients With Newly Diagnosed Glioblastoma

NCT04119674CompletedPhase 1
Zhejiang Cancer Hospital
Posted 3/19/2019

A Study of KL590586 in Patients With Advanced Solid Tumors

NCT05265091Active, Not RecruitingPhase 1
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Posted 6/1/2021

ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study

NCT04620239RecruitingPhase 3
Steba Biotech S.A.
Posted 3/22/2021

Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors

NCT05969041RecruitingPhase 1
Myeloid Therapeutics
Posted 8/2/2023

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia

NCT05384587Active, Not RecruitingPhase 2
Novartis Pharmaceuticals
Posted 11/11/2022

A Study of IBI363 in Subjects With Advanced Melanoma

NCT06081920RecruitingPhase 2
Innovent Biologics (Suzhou) Co. Ltd.
Posted 10/19/2023

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

NCT03336333Active, Not RecruitingPhase 3
BeiGene
Posted 10/31/2017

CTS2190 Phase I /II Clinical Study in Patients

NCT06224387RecruitingPhase 1
CytosinLab Therapeutics Co., Ltd.
Posted 6/26/2023

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04557098Active, Not RecruitingPhase 2
Janssen Research & Development, LLC
Posted 9/17/2020

Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11)

NCT03617003CompletedPhase 1
Memorial Sloan Kettering Cancer Center
Posted 8/1/2018

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

NCT05693766RecruitingPhase 2
Sonya Reid
Posted 9/11/2023

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

NCT04898634Active, Not RecruitingPhase 1
Janssen Research & Development, LLC
Posted 7/13/2021

Sequential Combo Immuno and Target Therapy (SECOMBIT) Study

NCT02631447CompletedPhase 2
Fondazione Melanoma Onlus
Posted 11/14/2016

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

NCT03400332Active, Not RecruitingPhase 1
Bristol-Myers Squibb
Posted 2/12/2018

Safety and Efficacy of Reduced-port Laparoscopic Surgery for Patients Of Colon and Upper Rectal Cancer

NCT05953662Active, Not RecruitingNot Applicable
Sixth Affiliated Hospital, Sun Yat-sen University
Posted 9/1/2023

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

NCT05029882Active, Not RecruitingPhase 1
AbbVie
Posted 10/13/2021

A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients

NCT06361927RecruitingPhase 2
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Posted 5/15/2024

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526Active, Not RecruitingPhase 1
OncoC4, Inc.
Posted 9/16/2020

A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT

NCT04995653CompletedPhase 1
Seres Therapeutics, Inc.
Posted 11/24/2021

A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT04632108Active, Not RecruitingPhase 1
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Posted 1/28/2021

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

NCT05445908RecruitingPhase 2
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Posted 8/17/2022

A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer

NCT04958239RecruitingPhase 1
Boehringer Ingelheim
Posted 10/18/2021

SKB264 Injection Vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

NCT05347134Active, Not RecruitingPhase 3
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Posted 6/10/2022

Newly Diagnosed Glioblastoma

NCT04959500Unknown StatusPhase 2
Sun Yat-sen University
Posted 6/10/2021

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.